Mycobacterium avium infection and AIDS: A therapeutic dilemma in rapid evolution

Jerrold J. Ellner, Mark J. Goldberger, David M. Parenti

Research output: Contribution to journalArticlepeer-review

Abstract

NOTE FROM DR. MERLE A. SANDE - The role of Mycobacterium avium as a pathogen in the human immunodeficiency virus-infected population has been confusing and controversial to clinicians who care for AIDS patients. The organism is commonly isolated from respiratory secretions of patients with other infections and often seems part of the resident flora; even when isolated from the bone marrow or bloodstream, its impact on the course of AIDS and contribution to systemic diseases are unknown. However, an increasing subset of patients without other documented opportunistic infections or malignancies has symptoms that respond to therapy directed against M. avium. Studies are in progress to evaluate chemotherapeutic agents. Accordingly, the subject is here reviewed and guidelines offered to infectious disease clinicians by one with a long-standing interest in mycobacterial disease who has made numerous contributions to the field.

Original languageEnglish (US)
Pages (from-to)1326-1335
Number of pages10
JournalJournal of Infectious Diseases
Volume163
Issue number6
StatePublished - Jun 1991
Externally publishedYes

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Immunology

Fingerprint Dive into the research topics of 'Mycobacterium avium infection and AIDS: A therapeutic dilemma in rapid evolution'. Together they form a unique fingerprint.

Cite this